Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05928598 · ClinicalTrials.gov registry record · NA
Goals for Epilepsy Clinic Visits Trial
A NA study of Drug Resistant Epilepsy, sponsored by University of Michigan.
- Recruiting
- Registry status
- NA
- Development phase
- 152
- Enrollment target
- 1
- Study location
NCT05928598: Recruiting NA study of Drug Resistant Epilepsy, sponsored by University of Michigan.
NCT05928598 is a NA study of Drug Resistant Epilepsy that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 152 participants, above the 11-participant average among 6 other Drug Resistant Epilepsy trials with a reported enrollment target (1282% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05928598, a NA study of Drug Resistant Epilepsy, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- NA
- Development phase
- 152 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to conduct a trial to assess whether patients that receive a tablet-based waiting room priority communication tool (the "Epilepsy Visit Planner") have improved outcomes compared to patients that do not receive the tool. The project's hypotheses are: * Patients that receive the Epilepsy Visit Planner will have improved patient-provider communication compared to the non-planner group. * Patients that receive the Epilepsy Visit Planner will have improved quality of life scores. * The Epilepsy Visit Planner will score highly on process measures of feasibility and acceptability, demonstrating suitability for future larger scale study. Additionally, there is a related survey project that is not part of the clinical trial and will not be included in this registration information.
Primary Outcome
This is a 10-item measure with Likert scale (range 1-5 for each response) with a score range of 10-50 (higher score indicating higher perceived efficacy in communicating with providers).
Conditions Studied
Interventions
- BEHAVIORAL Survey questionnaires
- BEHAVIORAL Epilepsy Visit Planner
- BEHAVIORAL Questionnaires for Providers
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2027-01-01 |
| Phase | NA |
What NCT05928598 shows while recruiting
NCT05928598 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, above the 11-participant average among 6 other Drug Resistant Epilepsy trials with a reported enrollment target (1282% higher).
The record links to 1 condition, with Drug Resistant Epilepsy appearing as the primary indexed condition, and to 3 interventions - of which Survey questionnaires is the first listed.
NCT05928598 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05928598 about?
NCT05928598 is a clinical study titled "Goals for Epilepsy Clinic Visits Trial". The purpose of this project is to conduct a trial to assess whether patients that receive a tablet-based waiting room priority communication tool (the "Epilepsy Visit Planner") have improved outcomes compared to patients that do not receive the tool. The project's hypotheses are: * Patients that r...
What is the current status of trial NCT05928598?
This trial is currently recruiting. It is a NA study. The enrollment target is 152 participants. The study started on 2023-09-27. Estimated completion is 2027-01-01.
What conditions does trial NCT05928598 study?
This clinical trial studies the following conditions: Drug Resistant Epilepsy.
What interventions are being tested in trial NCT05928598?
The interventions under investigation include: Survey questionnaires (BEHAVIORAL), Epilepsy Visit Planner (BEHAVIORAL), Questionnaires for Providers (BEHAVIORAL).
Who is sponsoring clinical trial NCT05928598?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05928598 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Resistant Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial
RECRUITING · NA
-
Infrared Photobiomodulation in Humans With Epilepsy
RECRUITING · NA
-
Novel Helmet Design in Patients With Seizures
COMPLETED · NA
-
Electrophysiologic Studies of Cognition in Epilepsy Patients
COMPLETED · NA
-
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
RECRUITING · Phase 2
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI